In This Issue

February 2016
Clinical Pharmacology & Therapeutics;Feb2016, Vol. 99 Issue 2, p123
Academic Journal
An introduction is presented which focuses on topics including deficiency in dihydropyrimidine dehydrogenase, drug-induced long QT syndrome, and biomarkers.


Related Articles

  • Frequent intragenic rearrangements of DPYD in colorectal tumours. van Kuilenburg, A B P; Etienne-Grimaldi, M-C; Mahamat, A; Meijer, J; Laurent-Puig, P; Olschwang, S; Gaub, M-P; Hennekam, R C M; Benchimol, D; Houry, S; Letoublon, C; Gilly, F-N; Pezet, D; Andre, T; Faucheron, J-L; Abderrahim-Ferkoune, A; Vijzelaar, R; Pradere, B; Milano, G // Pharmacogenomics Journal;Jun2015, Vol. 15 Issue 3, p211 

    Dihydropyrimidine dehydrogenase is a crucial enzyme for the degradation of 5-fluorouracil (5FU). DPYD, which encodes dihydropyrimidine dehydrogenase, is prone to acquire genomic rearrangements because of the presence of an intragenic fragile site FRA1E. We evaluated DPYD copy number variations...

  • A Case of 5-FU-Related Severe Toxicity Associated with the p.Y186C DPYD Variant. Zaanan, A; Dumont, L-M; Loriot, M-A; Taieb, J; Narjoz, C // Clinical Pharmacology & Therapeutics;Feb2014, Vol. 95 Issue 2, p136 

    A letter to the editor is presented in response to the article "A DPYD Variant (Y186C) in Individuals of African Ancestry Is Associated with Reduced DPD Enzyme Activity" by S.M. Offer and colleagues in the July 2013 issue.

  • Response to 'A Case of 5-FU-Related Severe Toxicity Associated With the P.Y186C DPYD Variant'. Offer, S M; Diasio, R B // Clinical Pharmacology & Therapeutics;Feb2014, Vol. 95 Issue 2, p137 

    A response from the author of the article "A Case of 5-FU-Related Severe Toxicity Associated With the P.Y186C DPYD Variant" in a 2013 issue is presented.

  • Reaction of 6-methyl-2-(2-oxo-2-phenyl-ethylidene)-2,3-dihydropyrimidin-4(1 H)-one with hydrazine and hydroxylamine. Yavolovskii, A.; Grishchuk, L.; Rakipov, I.; Stepanov, D.; Ivanov, Yu.; Kamalov, G. // Chemistry of Heterocyclic Compounds;Jan2013, Vol. 48 Issue 10, p1487 

    The reaction of 6-methyl-2-(2-oxo-2-phenylethylidene)-2,3-dihydropyrimidin-4(1 H)-one and of its nitrosation product with hydroxylamine stops at the stage of forming the corresponding oximes. The reaction of 6-methyl-2-(2-oxo-2-phenylethylidene)-2,3-dihydropyrimidin-4(1 H)-one with hydrazine...

  • Synthesis of ( S)-(-)-1,4-diaryl-6-methyl-4-trifluoromethyl-3,4-dihydropyrimidine-2(1 H)-thiones. Golovach, N.; Sukach, V.; Vovk, M. // Russian Journal of Organic Chemistry;Mar2012, Vol. 48 Issue 3, p430 

    ( S)-(+)-4-Amino-4-aryl-5,5,5-trifluoropentan-2-one reacted with aryl isothiocyanates containing electron-withdrawing substituents to give ( S)-(−)-1,4-diaryl-6-methyl-4-trifluoromethyl-3,4-dihydropyrimidine-2(1 H)-thiones.

  • Gimeracil/oteracil/tegafur.  // Reactions Weekly;Sep2015, Vol. 1567 Issue 1, p104 

    The article presents case report of a patient who developed anorexia following treatment with gimeracil/oteracil/tegafur for signet-ring adenocarcinoma.

  • Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio. Thomas, F; Hennebelle, I; Delmas, C; Lochon, I; Dhelens, C; Garnier Tixidre, C; Bonadona, A; Penel, N; Goncalves, A; Delord, JP; Toulas, C; Chatelut, E // Clinical Pharmacology & Therapeutics;Feb2016, Vol. 99 Issue 2, p235 

    Despite the growing evidence that dihydropyrimidine dehydrogenase deficiency (DPD, encoded by the DPYD gene) confers a higher risk of developing severe toxicity, most patients are not screened for DPD deficiency before fluoropyrimidine treatment. We report here the genetic and phenotypic...

  • Multiple drugs.  // Reactions Weekly;12/2/2016, Vol. 1630 Issue 1, p179 

    An abstract of the article "Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines" by D. Meulendijks and others is presented.

  • Pseudomonas putida PydR, a RutR-like transcriptional regulator, represses the dihydropyrimidine dehydrogenase gene in the pyrimidine reductive catabolic pathway. Hidese, Ryota; Mihara, Hisaaki; Kurihara, Tatsuo; Esaki, Nobuyoshi // Journal of Biochemistry;Oct2012, Vol. 152 Issue 4, p341 

    The pyrimidine reductive catabolic pathway is important for the utilization of uracil and thymine as sources of nitrogen and carbon. The pathway is controlled by three enzymes: dihydropyrimidine dehydrogenase (DPD), dihydropyrimidinase and β-alanine synthase. The putative DPD genes, pydX and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics